Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of hetrombopag in children and adolescents with chronic primary immune thrombocytopenia
CTR20210088Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in chronic primary immune thrombocytopenia (ITP), sponsored by Hengrui Therapeutics. Started Apr 2021; status: completed.
02
Drugs
hetrombopag
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20210088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210088.